Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Degarelix acetate prior to or with radiotherapy for prostate cancer	Degarelix acetate , Radiotherapy	Prostate cancer	Male Reproductive Cancer	2023	View \| Download
Deferiprone for transfusional iron overload in sickle cell disease and other anaemias – First Line	Deferiprone (Ferriprox)	Iron overload	Endocrine Nutritional and Metabolic Disorders , Haematology	2020	View \| Download
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer	Datopotamab deruxtecan (DS-1062)	Breast cancer	Breast Cancer	2024	View \| Download
Datopotamab deruxtecan for previously treated unresectable or metastatic HR+ HER2- breast cancer	Datopotamab deruxtecan (DS-1062)	Breast cancer	Breast Cancer	2023	View \| Download
Datopotamab deruxtecan for previously treated advanced non-small-cell lung cancer	Datopotamab deruxtecan (DS-1062)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Dasiglucagon for treating congenital hyperinsulinism	Dasiglucagon (ZP 4207)	Congenital hyperinsulinism , Hypoglycaemia	Endocrine Nutritional and Metabolic Disorders	2021	View \| Download
Dasatinib (Sprycel) tablets for children with type II variation, philadelphia positive acute lymphoblastic leukaemia	Dasatinib (Sprycel; BMS 354825; dasatinib monohydrate)	Acute lymphoblastic leukaemia (ALL)	Haematological Cancer and Lymphomas	2017	View \| Download
Darolutamide with androgen deprivation therapy for metastatic hormone sensitive prostate cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa)	Prostate cancer	Male Reproductive Cancer	2024	View \| Download
Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa) , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous)	Prostate cancer	Male Reproductive Cancer	2021	View \| Download
Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa)	Prostate cancer	Male Reproductive Cancer	2018	View \| Download